Universität zu Köln

Vay, Christian, Schlunder, Philipp M., Dizdar, Levent, Esposito, Irene, Ghadimi, Markus P. H., Knoefel, Wolfram T. and Krieg, Andreas ORCID: 0000-0003-2496-1079 (2022). Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment. J. Cancer Res. Clin. Oncol., 148 (3). S. 633 - 646. NEW YORK: SPRINGER. ISSN 1432-1335

Full text not available from this repository.

Abstract

Purpose Liposarcoma (LPS) represent the largest group of malignant soft tissue tumours comprising a heterogeneous group of subtypes in which the degrees of chemoresistance and radiosensitivity strongly vary. Consequently, it is of utmost interest to establish novel therapeutic regimens based on molecular targets. Methods Immunohistochemical staining of survivin was performed in tissue microarrays comprising 49 primary LPS specimens. LPS cell lines were treated with survivin antagonist YM155 and doxorubicin or etoposide alone as well as in combination. Changes in cell viability were investigated and the synergistic effect of a combined therapy analysed. Results Immunohistochemistry revealed an abundant expression of survivin in LPS that significantly concurred with less-differentiated tumour subtypes and grading. In vitro, we demonstrated the impact of the survivin inhibitor YM155 on dedifferentiated LPS (DDLPS) and, even more imposing, pleomorphic LPS (PLS) tumour cell viability with a strong induction of apoptosis. A combined treatment of doxorubicin or etoposide with YM155 augmented the cytotoxic effects on DDLPS and PLS cells. Conclusion These findings support the significant role of survivin in the oncogenesis and progression of LPS subtypes providing a rationale to target survivin in eligible in-vivo models and to pioneer clinical applications of survivin-specific substances unfolding their therapeutic potential in LPS patients prospectively.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Vay, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Schlunder, Philipp M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Dizdar, Levent UNSPECIFIED UNSPECIFIED UNSPECIFIED Esposito, Irene UNSPECIFIED UNSPECIFIED UNSPECIFIED Ghadimi, Markus P. H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Knoefel, Wolfram T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Krieg, Andreas UNSPECIFIED orcid.org/0000-0003-2496-1079 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-576563
DOI:	10.1007/s00432-021-03871-5
Journal or Publication Title:	J. Cancer Res. Clin. Oncol.
Volume:	148
Number:	3
Page Range:	S. 633 - 646
Date:	2022
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-1335
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PROGNOSTIC MARKER; MYXOID LIPOSARCOMA; GASTRIC-CANCER; XIAP; BIOMARKERS; EXTREMITY; CHEMOTHERAPY; MANAGEMENT; RESISTANCE; INHIBITOR Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/57656